Investors NewsSearch: Nov 03, 2026Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference Oct 29, 2026Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update Oct 29, 2026Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C Sep 30, 2026Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC) Jun 11, 2026Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results Jun 10, 2026Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C Apr 22, 2026Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease" Mar 16, 2026Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results Dec 11, 2025Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results Oct 29, 2025Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results 1 2 3 4 5 6 << < > >>
